-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although there are many drugs for psoriasis, there are still many patients who are not getting treatment or proper care
.
Generally speaking, patients of color tend to have more severe symptoms and worse quality of life, which may be due to misdiagnosis and/or lack of communication with medical institutions
Researchers enrolled 302 patients with psoriasis and conducted an online survey to assess health care barriers
.
The subjects randomly received one of two online surveys: mild psoriasis vs.
The results show that whether it is a subject with mild psoriasis symptoms or a subject with severe psoriasis symptoms, the severity of symptoms, willingness to seek medical attention, medical barriers, and the impact of the disease on daily life, white people There were no significant differences between the non-white population
.
However, compared with white patients, the lack of qualified care for people of color is one of the biggest obstacles to the treatment of psoriasis (χ2(2)=6.
In summary, the results of the study indicate that if medical staff can better understand psoriasis and medical barriers based on race and/or ethnic background, they are likely to improve their interaction with patients and the way they introduce treatment
Original source:
Jeremy K Bray, et al.
Differences in healthcare barriers based on racial and/or ethnic background for patients with psoriasisLeave a message here
